Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer.

abstract：:Seven small- (SCLC) and four non-small-cell (NSCLC) lung cancer cell lines were used to examine the in vitro cytotoxicity of cytotoxic drugs such as (1aS-(1a alpha,8 beta,8a alpha,8b alpha]-8-[aminocarbonyl)oxy)methyl)-4,8a- dimethoxy-1,1a,2,8,8a,8b-hexahydro-7-hydroxy-5-methyl-6- nitrosoazirino(2',3':3,4)-pyrrolo-(1,...

journal_title：Cancer chemotherapy and pharmacology

authors： Horiuchi N,Nakagawa K,Sasaki Y,Minato K,Fujiwara Y,Nezu K,Ohe Y,Saijo N

更新日期：1988-01-01 00:00:00

abstract：:Cyclophosphamide demonstrates enhanced tumoricidal activity with decreased bone marrow toxicity when given on a divided-dose schedule in certain animal models. A total of 22 patients presenting with refractory metastatic cancer were treated in a phase I trial of continuous infusion of cyclophosphamide over 96 h. Granu...

journal_title：Cancer chemotherapy and pharmacology

authors： Eder JP,Elias AD,Ayash L,Wheeler CA,Shea TC,Schnipper LE,Frei E 3rd,Antman KH

更新日期：1991-01-01 00:00:00

abstract：PURPOSE:Bevacizumab or temsirolimus regimens have clinical activity in the first-line treatment of advanced renal cell carcinoma (RCC). This phase I/II trial was conducted to determine the safety of combining both agents and its efficacy in RCC patients who progressed on at least one prior anti-VEGF receptor tyrosine k...

journal_title：Cancer chemotherapy and pharmacology

authors： Merchan JR,Qin R,Pitot H,Picus J,Liu G,Fitch T,Maples WJ,Flynn PJ,Fruth BF,Erlichman C

更新日期：2015-03-01 00:00:00

abstract：:A total of 22 relapsed or refractory ovarian cancer patients were treated with ifosfamide-containing polychemotherapy. Kinetic analyses were done to evaluate the tumor-cell-recruiting potential of the alkylating agent. Our study shows that ifosfamide can enhance tumor proliferative activity in pretreated ovarian cance...

journal_title：Cancer chemotherapy and pharmacology

authors： Rosso R,Alama A,Repetto L,Conte PF

更新日期：1990-01-01 00:00:00

abstract：OBJECTIVES:ATP-binding cassette subfamily C member 4 (ABCC4) encoding MRP4 protein is involved in pediatric acute lymphoblastic leukemia (ALL) drug resistance. The nonsynonymous single nucleotide polymorphism (SNP) rs2274407 (G912T; K304N) is located in the 3' splice acceptor site of exon 8 of ABCC4 pre-mRNA. The aim o...

journal_title：Cancer chemotherapy and pharmacology

authors： Mesrian Tanha H,Rahgozar S,Mojtabavi Naeini M

更新日期：2017-07-01 00:00:00

abstract：PURPOSE:To compare serum and urine levels of tamoxifen and metabolites after a loading dose and at the steady state. METHODS:A loading dose of 160 mg of tamoxifen was given to 14 patients with advanced breast cancer. Thereafter a regular daily dose of 30 mg of tamoxifen was given. Serum and urine levels of tamoxifen a...

journal_title：Cancer chemotherapy and pharmacology

authors： de Vos D,Slee PH,Briggs RJ,Stevenson D

更新日期：1998-01-01 00:00:00

abstract：:In five cancer patients we have determined the pharmacokinetics of 4'-deoxydoxorubicin (4'-DOX), its alcoholic metabolite 4'-deoxydoxorubicinol and the occurrence of circulating 7-deoxyaglycone metabolites. The 7-deoxyaglycone of the alcohol metabolite, the major aglycone of Adriamycin (ADR) present in man, was not de...

journal_title：Cancer chemotherapy and pharmacology

authors： Cummings J,Kerr DJ,Kaye SB

更新日期：1987-01-01 00:00:00

abstract：PURPOSE:miRNAs are implicated in drug resistance of multiple cancers including non-small cell lung cancer (NSCLC), highlighting the potential of miRNAs as chemoresistance regulators in cancer treatment. This study aims to explore the relationship between miR-181c and chemoresistance of NSCLC cells. METHODS:qRT-PCR was...

journal_title：Cancer chemotherapy and pharmacology

authors： Zhang H,Hu B,Wang Z,Zhang F,Wei H,Li L

更新日期：2017-11-01 00:00:00

abstract：:When tumor cell density increases, the cytotoxic activity of certain anticancer agents, such as vincristine (VCR) and doxorubicin (DXR), progressively decreases. This phenomenon is termed the inoculum effect. Since VCR and DXR are less active in an acidic environment, we questioned whether the inoculum effects could h...

journal_title：Cancer chemotherapy and pharmacology

authors： Kobayashi H,Takemura Y,Ohnuma T

更新日期：1992-01-01 00:00:00

abstract：BACKGROUND:Cediranib (RECENTIN™) is an oral, highly potent VEGF inhibitor. This study evaluated the effect of food on the pharmacokinetics of cediranib and compared the administration of continual cediranib via two dosing strategies using this as a platform to investigate pharmacodynamic imaging biomarkers. METHODS:Si...

journal_title：Cancer chemotherapy and pharmacology

authors： Mitchell CL,O'Connor JP,Roberts C,Watson Y,Jackson A,Cheung S,Evans J,Spicer J,Harris A,Kelly C,Rudman S,Middleton M,Fielding A,Tessier J,Young H,Parker GJ,Jayson GC

更新日期：2011-09-01 00:00:00

abstract：PURPOSE:5-Fluorouracil is the most commonly used drug for the treatment of colon cancer, yet clinical resistance to this drug is frequently observed in patients making this drug ineffective. Thus, identification of gene responsible for 5-FU resistance is of utmost importance. METHODS:Cellular cytotoxicity and expressi...

journal_title：Cancer chemotherapy and pharmacology

authors： Das D,Satapathy SR,Siddharth S,Nayak A,Kundu CN

更新日期：2015-09-01 00:00:00

abstract：:Cancer is a major health issue worldwide and the global burden of cancer is expected to reduce the costs of treatment as well as prolong the survival time. One of the promising approaches is drug repurposing, because it reduces costs and shortens the production cycle of research and development. Disulfiram (DSF), whic...

journal_title：Cancer chemotherapy and pharmacology

authors： Lu C,Li X,Ren Y,Zhang X

更新日期：2021-01-10 00:00:00

abstract：:Experimental data suggest that multidrug resistance in cancer may be overcome by using an increased dose of anticancer agent(s) in combination with a resistance-modifying agent (RMA). We studied the pharmacokinetics and metabolism of both epirubicin (EPI) and verapamil (VPL) to explore the possible pharmacokinetic int...

journal_title：Cancer chemotherapy and pharmacology

authors： Mross K,Hamm K,Hossfeld DK

更新日期：1993-01-01 00:00:00

abstract：:The pharmacokinetics of pentamethylmelamine (PMM) have been investigated in mouse (Balb C-, CBA/LAC, nude), rat (Wistar), and man. In all three species, PMM was extensively demethylated to N2,N2,N4,N6-tetramethylmelamine and N2,N4,N6-trimethylmelamine, although marked species differences in the rate of metabolism were...

journal_title：Cancer chemotherapy and pharmacology

authors： Rutty CJ,Newell DR,Muindi JR,Harrap KR

更新日期：1982-01-01 00:00:00

abstract：PURPOSE:Pemetrexed, a multi-targeted antifolate that disrupts synthesis of both purines and pyrimidines, is approved for use in malignant pleural mesothelioma and non-small cell lung cancer. Pemetrexed is currently being evaluated for anti-tumor activity in a variety of solid and central nervous system tumors. We studi...

journal_title：Cancer chemotherapy and pharmacology

authors： Stapleton SL,Reid JM,Thompson PA,Ames MM,McGovern RM,McGuffey L,Nuchtern J,Dauser R,Blaney SM

更新日期：2007-03-01 00:00:00

abstract：PURPOSE:D-Limonene is a natural monoterpene with pronounced chemotherapeutic activity and minimal toxicity in preclinical studies. A phase I clinical trial to assess toxicity, the maximum tolerated dose (MTD) and pharmacokinetics in patients with advanced cancer was followed by a limited phase II evaluation in breast c...

journal_title：Cancer chemotherapy and pharmacology

authors： Vigushin DM,Poon GK,Boddy A,English J,Halbert GW,Pagonis C,Jarman M,Coombes RC

更新日期：1998-01-01 00:00:00

abstract：:Nanoparticulate carriers of anthracyclines are being developed with the aim of improving the pharmacokinetic or pharmacodynamic behavior of these drugs. To understand how the drug reaches its nuclear targets, we have developed two methods that allow the quantification of the interaction between an anthracycline and ce...

journal_title：Cancer chemotherapy and pharmacology

authors： Bogush T,Smirnova G,Shubina I,Syrkin A,Robert J

更新日期：1995-01-01 00:00:00

abstract：PURPOSE:We reported the first case of phenytoin intoxication due to the concomitant use of phenytoin and TS-1, together with a review of the literature regarding the occurrence of phenytoin intoxication due to the concomitant use of phenytoin and fluoropyrimidine antitumor drugs such as fluorouracil (5-FU) and tegafur ...

journal_title：Cancer chemotherapy and pharmacology

authors： Tsuda A,Fujiyama J,Miki A,Hori S,Ohtani H,Sawada Y

更新日期：2008-08-01 00:00:00

abstract：PURPOSE:S-1 has systemic activity for locally advanced pancreatic cancer (LAPC). Here, the efficacy and safety of induction gemcitabine (GEM) and S-1 (GS) followed by chemoradiotherapy (CRT) and systemic chemotherapy using S-1 for LAPC were assessed. METHODS:The treatment consisted of four cycles of induction GS (S-1 ...

journal_title：Cancer chemotherapy and pharmacology

authors： Sudo K,Hara R,Nakamura K,Kita E,Tsujimoto A,Yamaguchi T

更新日期：2017-07-01 00:00:00

abstract：:A 44-year-old man who had achieved a complete remission of malignant peritoneal mesothelioma after the intraperitoneal administration of 25 mg/m2 mitoxantrone presented with clinical and radiological signs of intestinal obstruction suggestive of recurrent disease at about 2 years following the initial treatment. Howev...

journal_title：Cancer chemotherapy and pharmacology

authors： Vlasveld LT,Taal BG,Kroon BB,Gallee MP,Rodenhuis S

更新日期：1992-01-01 00:00:00

abstract：:We studied the release of histamine elicited by some antineoplastic drugs in rat pleural and peritoneal mast cells. The drugs tested included the antibiotic mitomycin; the anthracyclines daunorubicin, doxorubicin, and epirubicin; the glycopeptide bleomycin; the chromopeptide dactinomycin; the platinum coordination com...

journal_title：Cancer chemotherapy and pharmacology

authors： Botana LM,Arnaez E,Vieytes MR,Alfonso A,Louzao MC

更新日期：1992-01-01 00:00:00

abstract：:Carboxypeptidase G2 (CPG2) is used when unexpected toxicity or renal failure occurs during high-dose methotrexate therapy. Leucovorin is also administered to antagonise the effects of methotrexate on purine anabolism. To investigate the effects of CPG2 on leucovorin rescue, we incubated the enzyme with both stereoisom...

journal_title：Cancer chemotherapy and pharmacology

authors： Hempel G,Lingg R,Boos J

更新日期：2005-04-01 00:00:00

abstract：:Increasing the expression of human multidrug resistance (MDR) 1 gene in bone marrow cells to prevent or circumvent bone morrow toxicity from chemotherapy agent is a high priority of dose intensification protocols. In this study, we have used a tumor-bearing model to investigate the chemoprotection effect of MDR1 gene ...

journal_title：Cancer chemotherapy and pharmacology

authors： Guo CB,Li YC,Jin XQ

更新日期：2006-07-01 00:00:00

abstract：PURPOSE:Transcatheter arterial chemoembolization (TACE) causes damage to liver function and decreases the activity of cytochrome P450 in patients with hepatocellular carcinoma (HCC). But there was no report on whether the activity of Phase II conjugating enzymes was affected in HCC patients after TACE treatment. The pu...

journal_title：Cancer chemotherapy and pharmacology

authors： Zhang Y,Jia Y,Liu X,Liu L,Wang Q,Wen A

更新日期：2010-01-01 00:00:00

abstract：:Imidazoacridinones are a new class of highly potent antineoplastic agents synthesised at the Technical University of Gdansk. The pharmacophoric alkyldiamine group, which is also present in anthracenediones (e.g. ametantrone, mitoxantrone), has been shown to be responsible for their antineoplastic activity. In view of ...

journal_title：Cancer chemotherapy and pharmacology

authors： Augustin E,Wheatley DN,Lamb J,Konopa J

更新日期：1996-01-01 00:00:00

abstract：PURPOSE:Streptozocin (STZ) is a key agent for treating advanced pancreatic neuroendocrine tumors (pNET). Most STZ regimens for pNET are daily and also include 5-fluorouracil (5FU), whereas STZ monotherapy and weekly regimens have also been applied in daily practice in Japan. The present study aimed to evaluate response...

journal_title：Cancer chemotherapy and pharmacology

authors： Shibuya H,Hijioka S,Sakamoto Y,Ito T,Ueda K,Komoto I,Kobayashi N,Kudo A,Yasuda H,Miyake H,Arita J,Kiritani S,Ikeda M,Imaoka H,Ueno M,Kobayashi S,Furuta M,Nagashio Y,Murohisa G,Aoki T,Matsumoto S,Motoya M,Azemo

更新日期：2018-10-01 00:00:00

abstract：PURPOSE:The present study was designed to investigate the ability of N-[4-(5-bromo-2-pyrimidyloxy)-3-methylphenyl]-(dimemethylamino)-benzoylphenylurea (dimemethylamino benzoylphenylurea; BPU) to sensitize cells to radiation and to examine the relationship between phenotype versus survival, DNA damage, apoptosis, or cel...

journal_title：Cancer chemotherapy and pharmacology

authors： Balcer-Kubiczek EK,Attarpour M,Edelman MJ

更新日期：2007-05-01 00:00:00

abstract：:The selective Aurora-A kinase inhibitor MLN8237 is in clinical trials for hematologic malignancies, ovarian cancer and other solid tumors. We previously showed that MLN8237 is potently antiproliferative toward standard monolayer-cultured glioblastoma cells. We have now investigated the effect of MLN8237 with and witho...

journal_title：Cancer chemotherapy and pharmacology

authors： Hong X,O'Donnell JP,Salazar CR,Van Brocklyn JR,Barnett KD,Pearl DK,deCarvalho AC,Ecsedy JA,Brown SL,Mikkelsen T,Lehman NL

更新日期：2014-05-01 00:00:00

abstract：PURPOSE:To determine the maximum recommended dose (RD) and pharmacokinetics of Myocet®, a non-pegylated liposomal doxorubicin, in children. METHODS:Eligible patients were children with refractory high-grade glioma who had received prior chemotherapy and radiotherapy but no anthracyclines. Cohorts of at least three pat...

journal_title：Cancer chemotherapy and pharmacology

authors： Chastagner P,Devictor B,Geoerger B,Aerts I,Leblond P,Frappaz D,Gentet JC,Bracard S,André N

更新日期：2015-08-01 00:00:00

abstract：:D-3-Azido-3-deoxy-myo-inositol (3AMI) is an inhibitor of the growth of v-sis-transformed NIH 3T3 cells but not of wild-type NIH 3T3 cells, whose effects may be mediated through the phosphatidylinositol-3'-kinase pathway. We studied some properties of the cellular pharmacology of 3AMI using high-specific-activity [3H]-...

journal_title：Cancer chemotherapy and pharmacology

authors： Brunn G,Fauq AH,Chow S,Kozikowski AP,Gallegos A,Powis G

更新日期：1994-01-01 00:00:00